Openbookopenbook
Equity
hVIVO plc(HVO)
GBX --+0.00%
Reward75High
Risk41Moderate
📊75%Data
2.5% dividend yield · Revenue down 32% YoY
HVO
+0.0 · +0.00%
GBX · LSE
hVIVO plc | Healthcare
Quality Compounder
Market Cap:55.32M
ℹ️
Reward Rating
75
High
Top 10% (model universe)
75% data coverage
ℹ️
Risk Rating
41
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on HVO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 18p.

What is hVIVO plc?

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America.

HVO · Verdict

Strong reward · moderate risk

HVO stands out on valuation and balance sheet, but watch the volatility signal.

Based on 88% data coverage

HVO · Verdict

What’s working & what to watch

Strengths 5

  • Valuation93/100

    P/E 11.2×

  • Balance sheet93/100

    Interest covered 12.8×

  • Profitability84/100

    17% net margin · 13% ROE

  • Growth78/100

    Revenue +19.4% CAGR

  • Cash flow66/100

    13% free-cash-flow margin

Watchouts 1

  • Volatility20/100

    Weak vs peers

Model-based scoring. For information only — not financial advice.

What is hVIVO plc?

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 55.32M, and a P/E ratio of 8.1x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: High (75)

The scoring profile indicates a strong reward potential, driven primarily by valuation and profitability. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap55.32M
P/E Ratio8.05
Dividend Yield2.49%
52 Week High19.2803
52 Week Low4.305
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding687M
No. of Employees301
IndustryDiagnostics & Research
ExchangeLSE
Beta1.604
CurrencyGBX · Reports in GBP
Websitewww.hvivo.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.